Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 567486, 14 pages
http://dx.doi.org/10.1155/2009/567486
Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Division of Hematology and Medical Oncology, J. G. Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA

Received 26 November 2008; Accepted 30 January 2009

Academic Editor: Daniel Chua

Copyright © 2009 Amir Harandi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [64 citations]

The following is the list of published articles that have cited the current article.

  • Philomena Charlotte Dsouza, and Shiyam Kumar, “Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities.,” Asia-Pacific journal of oncology nursing, vol. 4, no. 4, pp. 323–329, . View at Publisher · View at Google Scholar
  • Seunguk Oh, Brad J. Stish, Deepali Sachdev, Hua Chen, Arkadiusz Z. Dudek, and Daniel A. Vallera, “A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma,” Clinical Cancer Research, vol. 15, no. 19, pp. 6137–6147, 2009. View at Publisher · View at Google Scholar
  • Sabrina Oliveira, Raymond M. Schiffelers, Joris van der Veeken, Roy van der Meel, Ranitha Vongpromek, Paul M. P. van Bergen En Henegouwen, Gert Storm, and Rob C. Roovers, “Downregulation of EGFR by a novel multivalent nanobody-liposome platform,” Journal of Controlled Release, vol. 145, no. 2, pp. 165–175, 2010. View at Publisher · View at Google Scholar
  • Laurent, Geboes, and Peeters, “The impact of genetics in the treatment of colorectal tumours,” Tijdschrift voor Geneeskunde, vol. 66, no. 21, pp. 1029–1033, 2010. View at Publisher · View at Google Scholar
  • Victor M. Duarte, Eugene Han, Mysore S. Veena, Amanda Salvado, Jeffrey D. Suh, Li-Jung Liang, Kym F. Faull, Eri S. Srivatsan, and Marilene B. Wang, “Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFβB pathway,” Molecular Cancer Therapeutics, vol. 9, no. 10, pp. 2665–2675, 2010. View at Publisher · View at Google Scholar
  • Florian Kampmeier, Judith Niesen, Alexander Koers, Markus Ribbert, Andreas Brecht, Rainer Fischer, Fabian Kiessling, Stefan Barth, and Theo Thepen, “Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein,” European Journal Of Nuclear Medicine And Molecular Imaging, vol. 37, no. 10, pp. 1926–1934, 2010. View at Publisher · View at Google Scholar
  • Dimitrios Chatsiproios, “Safety profile and clinical recommendations for the use of lapatinib,” Breast Care, vol. 5, no. 1, pp. 16–21, 2010. View at Publisher · View at Google Scholar
  • Niels Jorgen Ostergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjaersgaard Jorgensen, Adam Hey, and Michael Kragh, “Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor,” Clinical Cancer Research, vol. 17, no. 18, pp. 5962–5972, 2011. View at Publisher · View at Google Scholar
  • Estefania Carrasco-Garcia, Miguel Saceda, Silvina Grasso, Lourdes Rocamora-Reverte, Mariano Conde, Angeles Gomez-Martinez, Pilar Garcia-Morales, Jose A. Ferragut, and Isabel Martinez-Lacaci, “Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines,” Experimental Cell Research, vol. 317, no. 10, pp. 1476–1489, 2011. View at Publisher · View at Google Scholar
  • Robbert Jan Kok, Raymond Schiffelers, and Isil Altintas, “Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer,” Current Signal Transduction Therapy, vol. 6, no. 2, pp. 267–278, 2011. View at Publisher · View at Google Scholar
  • S Parmar, C Schumann, S Rüdiger, S Boeck, V Heinemann, V Kächele, A Seeringer, T Paul, T Seufferlein, and J C Stingl, “Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity,” The Pharmacogenomics Journal, vol. 13, no. 2, pp. 181–188, 2011. View at Publisher · View at Google Scholar
  • Stefan Langhammer, Robert Koban, Constanze Yue, and Heinz Ellerbrok, “Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa™),” Antiviral Research, vol. 89, no. 1, pp. 64–70, 2011. View at Publisher · View at Google Scholar
  • Sarice R. Boston, Rahul Deshmukh, Scott Strome, U. Deva Priyakumar, Alexander D. MacKerell, and Paul Shapiro, “Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9,” Bmc Cancer, vol. 11, 2011. View at Publisher · View at Google Scholar
  • Jean M. Torrisi, Lawrence H. Schwartz, Marc J. Gollub, Michelle S. Ginsberg, George J. Bosl, and Hedvig Hricak, “CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity,” Radiology, vol. 258, no. 1, pp. 41–56, 2011. View at Publisher · View at Google Scholar
  • Malabika Sen, Jennifer R. Grandis, Sonali Joyce, Mary Panahandeh, Changyou Li, Sufi M. Thomas, Jessica Maxwell, Lin Wang, William E. Gooding, and Daniel E. Johnson, “Targeting Stat3 abrogates EGFR inhibitor resistance in cancer,” Clinical Cancer Research, vol. 18, no. 18, pp. 4986–4996, 2012. View at Publisher · View at Google Scholar
  • Seunguk Oh, Deborah A. Todhunter, Angela Panoskaltsis-Mortari, Donald J. Buchsbaum, Shoko Toma, and Daniel A. Vallera, “A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Anti-Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model,” Pancreas, vol. 41, no. 5, pp. 789–796, 2012. View at Publisher · View at Google Scholar
  • J. T. Hartmann, C. Kollmannsberger, I. Cascorbi, F. Mayer, M. M. Schittenhelm, S. Heeger, and C. Bokemeyer, “A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer,” Investigational New Drugs, vol. 31, no. 3, pp. 661–668, 2012. View at Publisher · View at Google Scholar
  • Fenlai Tan, Xiaoyan Shen, Dechang Wang, Guojian Xie, Xiaodong Zhang, Lieming Ding, Yunyan Hu, Wei He, Yanping Wang, and Yinxiang Wang, “Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies,” Lung Cancer, vol. 76, no. 2, pp. 177–182, 2012. View at Publisher · View at Google Scholar
  • Roy van der Meel, Sabrina Oliveira, Isil Altintas, Rob Haselberg, Joris van der Veeken, Rob C. Roovers, Paul M. P. van Bergen En Henegouwen, Gert Storm, Wim E. Hennink, Raymond M. Schiffelers, and Robbert J. Kok, “Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment,” Journal Of Controlled Release, vol. 159, no. 2, pp. 281–289, 2012. View at Publisher · View at Google Scholar
  • V. Hirsh, B. Melosky, G. Goss, D. Morris, and W. Morzycki, “A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada,” Current Oncology, vol. 19, no. 2, pp. 78–90, 2012. View at Publisher · View at Google Scholar
  • Isil Altintas, Robbert Jan Kok, and Raymond M. Schiffelers, “Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies,” European Journal Of Pharmaceutical Sciences, vol. 45, no. 4, pp. 399–407, 2012. View at Publisher · View at Google Scholar
  • Dorothy M. K. Keefe, and Emma H. Bateman, “Tumor control versus adverse events with targeted anticancer therapies,” Nature Reviews Clinical Oncology, vol. 9, no. 2, pp. 98–109, 2012. View at Publisher · View at Google Scholar
  • Sarah H. Landis, Iman A. El-Hariry, Myrthe P. P. van Herk-Sukel, Pieter van den Haak, Maryska L. G. Janssen-Heijnen, Fernie J. A. Penning-van Beest, and Ron M. C. Herings, “Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck,” Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck, vol. 34, no. 2, pp. 238–244, 2012. View at Publisher · View at Google Scholar
  • Kazufumi Ohshiro, Tri M. Bui-Nguyen, Reddy S. Divijendra Natha, Arnold M. Schwartz, Paul Levine, and Rakesh Kumar, “Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-pak1 pathway,” International Journal of Biological Markers, vol. 27, no. 4, pp. e305–e313, 2012. View at Publisher · View at Google Scholar
  • Sabrina Oliveira, Raimond Heukers, Jirawas Sornkom, Robbert J. Kok, and Paul M.P. van Bergen en Henegouwen, “Targeting tumors with nanobodies for cancer imaging and therapy,” Journal of Controlled Release, 2013. View at Publisher · View at Google Scholar
  • Joanne M. Bowen, “Mechanisms of TKI-induced diarrhea in cancer patients,” Current Opinion in Supportive and Palliative Care, vol. 7, no. 2, pp. 162–167, 2013. View at Publisher · View at Google Scholar
  • James Chih-Hsin Yang, Noemi Reguart, Jana Barinoff, Jens Köhler, Martina Uttenreuther-Fischer, Uz Stammberger, Dennis O'Brien, Jürgen Wolf, and Ezra Ew Cohen, “Diarrhea associated with afatinib: An oral ErbB family blocker,” Expert Review of Anticancer Therapy, vol. 13, no. 6, pp. 729–736, 2013. View at Publisher · View at Google Scholar
  • Linda S. Elting, Yu-Chia Chang, Pratibha Parelkar, Christine B. Boers-Doets, Marisol Michelet, Guido Hita, Tanya Rouleau, Catherine Cooksley, Josiah Halm, Madhuri Vithala, Paolo Bossi, Carmen Escalante, and Michael T. Brennan, “Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis,” Supportive Care in Cancer, 2013. View at Publisher · View at Google Scholar
  • Jean-Charles Soria, José Baselga, Nasser Hanna, Scott A. Laurie, Rastislav Bahleda, Enriqueta Felip, Emiliano Calvo, Jean-Pierre Armand, Frances A. Shepherd, Christopher T. Harbison, David Berman, Jong-Soon Park, Steven Zhang, Blisse Vakkalagadda, John F. Kurland, Ashutosh K. Pathak, and Roy S. Herbst, “Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours,” European Journal of Cancer, vol. 49, no. 8, pp. 1815–1824, 2013. View at Publisher · View at Google Scholar
  • O. Sedlaczek, C. Grüllich, M. Röthke, H.-P. Schlemmer, and H.-U. Kauczor, “Organtoxizität medikamentöser Tumortherapien,” Der Radiologe, vol. 53, no. 4, pp. 329–335, 2013. View at Publisher · View at Google Scholar
  • Dhakshina Moorthy Ganeshan, Usama Salem, Chitra Viswanathan, Aparna Balachandran, Naveen Garg, Paul Silverman, and Priya Bhosale, “Complications of oncologic therapy in the abdomen and pelvis: a review,” Abdominal Imaging, vol. 38, no. 1, pp. 1–21, 2013. View at Publisher · View at Google Scholar
  • Darrell J. Irvine, Xingfang Su, and Brandon KwongPharmaceutical Sciences Encyclopedia, pp. 1–48, 2013. View at Publisher · View at Google Scholar
  • Marnix G. E. H. Lam, Arjun Banerjee, John D. Louie, and Daniel Y. Sze, “Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization,” CardioVascular and Interventional Radiology, 2013. View at Publisher · View at Google Scholar
  • Stefan Langhammer, “Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options (Review),” Oncology Reports, vol. 30, no. 4, pp. 1535–1541, 2013. View at Publisher · View at Google Scholar
  • Barbara Melosky, and Vera Hirsh, “Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs,” Frontiers in Oncology, vol. 4, 2014. View at Publisher · View at Google Scholar
  • Liesbeth Cornelissen, Filip Claus, Pascal Wolter, Herlinde Dumez, Frederik De Keyzer, Evelyne Lerut, Hendrik Van Poppel, and Benoit Beuselinck, “Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib,” European Radiology, 2014. View at Publisher · View at Google Scholar
  • Chitra Viswanathan, Mylene T. Truong, Tara L. Sagebiel, Yulia Bronstein, Raghunandan Vikram, Madhavi Patnana, Paul M. Silverman, and Priya R. Bhosale, “Abdominal and Pelvic Complications of Nonoperative Oncologic Therapy,” RadioGraphics, vol. 34, no. 4, pp. 941–961, 2014. View at Publisher · View at Google Scholar
  • M. A. Pessi, N. Zilembo, E. R. Haspinger, L. Molino, S. Di Cosimo, and M. Garassino, “Targeted therapy-induced diarrhea: A review of the literature,” Critical Reviews in Oncology Hematology, vol. 90, no. 2, pp. 165–179, 2014. View at Publisher · View at Google Scholar
  • Jiangmei Li, Lunfeng Zhang, Zhen Gao, Hua Kang, Guohua Rong, Xu Zhang, and Chang Chen, “Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy,” Protein & Cell, 2014. View at Publisher · View at Google Scholar
  • Wang Ma, Mingxin Xu, Yiqian Liu, Hao Liu, Jiale Huang, Yanjie Zhu, Li-juan Ji, and Xiaolong Qi, “Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  • V. Hirsh, N. Blais, R. Burkes, S. Verma, and K. Croitoru, “Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors,” Current Oncology, vol. 21, no. 6, pp. 329–336, 2014. View at Publisher · View at Google Scholar
  • Joanne M. Bowen, “Development of the Rat Model of Lapatinib-Induced Diarrhoea,” Scientifica, vol. 2014, pp. 1–6, 2014. View at Publisher · View at Google Scholar
  • Yuanjie Hu, Yi-Hong Zhou, Hengjun Gao, Christopher Vo, Chao Ke, Francine Pan, Liping Yu, Eric Siegel, Kenneth R. Hess, and Mark E. Linskey, “Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis,” Oncoscience, vol. 1, no. 3, pp. 205–215, 2014. View at Publisher · View at Google Scholar
  • Lorenza Landi, and Federico Cappuzzo, “Experience with erlotinib in the treatment of non-small cell lung cancer,” Therapeutic Advances In Respiratory Disease, vol. 9, no. 4, pp. 146–163, 2015. View at Publisher · View at Google Scholar
  • R. Califano, N. Tariq, S. Compton, D. A. Fitzgerald, C. A. Harwood, R. Lal, J. Lester, J. McPhelim, C. Mulatero, S. Subramanian, A. Thomas, N. Thatcher, and M. Nicolson, “Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK,” Drugs, 2015. View at Publisher · View at Google Scholar
  • D. E. Peterson, C. B. Boers-Doets, R. J. Bensadoun, and J. Herrstedt, “Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up,” Annals of Oncology, pp. mdv202, 2015. View at Publisher · View at Google Scholar
  • B. Melosky, N. B. Leighl, J. Rothenstein, R. Sangha, D. Stewart, and K. Papp, “Management of EGFR TKI-induced dermatologic adverse events,” Current Oncology, vol. 22, no. 2, pp. 123–132, 2015. View at Publisher · View at Google Scholar
  • Wei-Ling Lin, Yi-Shiuan Lin, Guey-Yueh Shi, Chuan-Fa Chang, and Hua-Lin Wu, “Lewis(y) Promotes Migration of Oral Cancer Cells by Glycosylation of Epidermal Growth Factor Receptor,” Plos One, vol. 10, no. 3, 2015. View at Publisher · View at Google Scholar
  • Feliciano Barron, Martha de la Torre-Vallejo, Rosa Luz Luna-Palencia, Andres F Cardona, and Oscar Arrieta, “The safety of afatinib for the treatment of non-small cell lung cancer,” Expert Opinion on Drug Safety, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  • Adam R. Johnson, Pawan Bir Kohli, Arna Katewa, Emily Gogol, Lisa D. Belmont, Regina Choy, Elicia Penuel, Luciana Burton, Charles Eigenbrot, Christine Yu, Daniel F. Ortwine, Krista Bowman, Yvonne Franke, Christine Tam, Alberto Estevez, Kyle Mortara, Jiansheng Wu, Hong Li, May Lin, Philippe Bergeron, James J. Crawford, and Wendy B. Young, “Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations,” ACS Chemical Biology, 2016. View at Publisher · View at Google Scholar
  • Ju Hou, Shanhe Wan, Guangfa Wang, Tingting Zhang, Zhonghuang Li, Yuanxin Tian, Yonghuan Yu, Xiaoyun Wu, and Jiajie Zhang, “Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor,” European Journal of Medicinal Chemistry, vol. 118, pp. 276–289, 2016. View at Publisher · View at Google Scholar
  • Bonnie K. Harrington, Duncan S. Russell, Xiaoli Zhang, Bridget K. Urie, Amy J. Johnson, William C. Kisseberth, Raquel Izumi, Ahmed Hamdy, Kevin R. Coombes, Todd Covey, Allard Kaptein, Bart Van Lith, Cecile Krejsa, Christopher C. Coss, Cheryl A. London, John C. Byrd, Heather L. Gardner, Wayne Rothbaum, and Michael Gulrajani, “Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma,” PLoS ONE, vol. 11, no. 7, 2016. View at Publisher · View at Google Scholar
  • Dahai Ren, Yiqiu Xia, Bin Wang, and Zheng You, “Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes,” Analytical Chemistry, 2016. View at Publisher · View at Google Scholar
  • F He, M R Verneris, S Cooley, B R Blazar, M L MacMillan, L F Newell, A Panoskaltsis-Mortari, T DeFor, D J Weisdorf, and S G Holtan, “Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation,” Bone Marrow Transplantation, 2016. View at Publisher · View at Google Scholar
  • Harriet S. Walter, Simon A. Rule, Martin J. S. Dyer, Lionel Karlin, Ceri Jones, Bruno Cazin, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Hideyuki Honda, Kevin Duffy, Joseph Birkett, Virginia Jamieson, Nigel Courtenay-Luck, Toshio Yoshizawa, John Sharpe, Tomoya Ohno, Shinichiro Abe, Akihisa Nishimura, Guillaume Cartron, Franck Morschhauser, Christopher Fegan, and Gilles Salles, “A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies,” Blood, vol. 127, no. 4, pp. 411–419, 2016. View at Publisher · View at Google Scholar
  • Atasha Asmat, Brendan Pang, Ross Andrew Soo, Nesaretnam Barr Kumarakulasinghe, Nicholas Syn, Yu Yang Soon, Huili Zheng, and En Yun Loy, “EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction,” Oncotarget, vol. 7, no. 51, pp. 85542–85550, 2016. View at Publisher · View at Google Scholar
  • Chia-Yu Chu, Kuan-Yu Chen, John Wen-Cheng Chang, Yu-Fong Wei, Chih-Hung Lee, and Wei-Ming Wang, “Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities,” Journal of the Formosan Medical Association, 2017. View at Publisher · View at Google Scholar
  • Osamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, Ayae Suzuki, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, and Noriyuki Namiki, “Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats,” Xenobiotica, pp. 1–7, 2017. View at Publisher · View at Google Scholar
  • S. Eldridge, and M. Davis, “Antineoplastic Agents ?,” Reference Module in Biomedical Sciences, 2017. View at Publisher · View at Google Scholar
  • Ken-Ichi Fujita, Hiroo Ishida, Yutaro Kubota, and Yasutsuna Sasaki, “Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacoth erapy: Management with clinical pharmacology,” Current Drug Metabolism, vol. 18, no. 3, pp. 186–198, 2017. View at Publisher · View at Google Scholar
  • Sean D. Reiff, Elizabeth M. Muhowski, Daphne Guinn, Amy Lehman, Catherine A. Fabian, Carolyn Cheney, Rose Mantel, Lisa Smith, Amy J. Johnson, Wendy B. Young, Adam R. Johnson, Lichuan Liu, John C. Byrd, and Jennifer A. Woyach, “Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL,” Blood, vol. 132, no. 10, pp. 1039–1049, 2018. View at Publisher · View at Google Scholar
  • Eva Calviño, Carmen Aizpurua, Ignacio Casal, Sofía Torres, Juan I. Imbaud, Ruben A. Bartolome, and Marta Jaen, “Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis,” Clinical Cancer Research, vol. 24, no. 2, pp. 433–444, 2018. View at Publisher · View at Google Scholar
  • Kristy Pilbeam, Elizabeth Taras, Rachel J. Bergerson, Todd DeFor, Hongbo Wang, Brianna Ettestad, Daniel A. Vallera, Antonella Borgatti, and Michael R. Verneris, “Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors,” Oncotarget, vol. 9, no. 15, pp. 11938–11947, 2018. View at Publisher · View at Google Scholar
  • David S. Lee, Jennifer R. Grandis, and Daniel E. Johnson, “STAT3 as a Major Contributor to Chemoresistance,” Targeting Cell Survival Pathways to Enhance Response to Chemotherapy, pp. 145–167, 2019. View at Publisher · View at Google Scholar